ReviewMolecules (Basel, Switzerland)2021
The Role of Serotonin in Breast Cancer Stem Cells.
Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- The neuroimmune axis in breast cancer: from mechanistic insights to clinical applications.BMC medicine · 2026Review
- MRPS28 serves as a biomarker of diagnostic, prognostic, and immune modulation in pan-cancer and promotes breast cancer malignant phenotypes.Frontiers in immunology · 2026Article
- Psychosomatics at the threshold: cancer, mood disorders, and the mental pain of death - where precision medicine meets spirituality.Frontiers in psychiatry · 2026Article
- Mechanistic insights into daidzin from Glycine max against breast cancer via network pharmacology and multi-level molecular modeling.PloS one · 2026Article
- Article
- Depression, antidepressant use, and breast cancer incidence: results from the E3N prospective cohort.Psychiatry and clinical neurosciences · 2025Article
- Comprehensive exploration of signal sequence receptor subunit 1 (SSR1) as a diagnostic and prognostic biomarker in liver hepatocellular carcinoma.American journal of translational research · 2025Article
- Article
- PPAR-γ agonists reactivate the ALDOC-NR2F1 axis to enhance sensitivity to temozolomide and suppress glioblastoma progression.Cell communication and signaling : CCS · 2024Article
- The therapeutic effect of traditional Chinese medicine on breast cancer through modulation of the Wnt/β-catenin signaling pathway.Frontiers in pharmacology · 2024Review
- Antidepressant Sertraline Hydrochloride Inhibits the Growth of HER2+ AU565 Breast Cancer Cell Line through Induction of Apoptosis and Cell Cycle Arrest.Anti-cancer agents in medicinal chemistry · 2024Article
- Article
- How cancer hijacks the body's homeostasis through the neuroendocrine system.Trends in neurosciences · 2023Review
- Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions.Oncogene · 2023Review
- Exploring neurotransmitters and their receptors for breast cancer prevention and treatment.Theranostics · 2023Review
- Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway.BMC cancer · 2022Article
- Computationally repurposing drugs for breast cancer subtypes using a network-based approach.BMC bioinformatics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Breast tumors were the first tumors of epithelial origin shown to follow the cancer stem cell model. The model proposes that cancer stem cells are uniquely endowed with tumorigenic capacity and that their aberrant differentiation yields non-tumorigenic progeny, which constitute the bulk of the tumor cell population. Breast cancer stem cells resist therapies and seed metastases; thus, they account for breast cancer recurrence. Hence, targeting these cells is essential to achieve durable breast cancer remissions. We identified compounds including selective antagonists of multiple serotonergic system pathway components required for serotonin biosynthesis, transport, activity via multiple 5-HT receptors (5-HTRs), and catabolism that reduce the viability of breast cancer stem cells of both mouse and human origin using multiple orthologous assays. The molecular targets of the selective antagonists are expressed in breast tumors and breast cancer cell lines, which also produce serotonin, implying that it plays a required functional role in these cells. The selective antagonists act synergistically with chemotherapy to shrink mouse mammary tumors and human breast tumor xenografts primarily by inducing programmed tumor cell death. We hypothesize those serotonergic proteins of diverse activity function by common signaling pathways to maintain cancer stem cell viability. Here, we summarize our recent findings and the relevant literature regarding the role of serotonin in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.